Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OXYCODONE AND ACETAMINOPHEN vs HYDROMORPHONE HYDROCHLORIDE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Oxycodone is a full mu-opioid receptor agonist, producing analgesia via activation of descending inhibitory pathways, while acetaminophen is a centrally acting analgesic and antipyretic, likely through inhibition of cyclooxygenase (COX) in the CNS and modulation of serotonergic pathways.
Hydromorphone is a full mu-opioid receptor agonist. It binds to mu-opioid receptors in the CNS, activating G-protein coupled receptors that inhibit adenylate cyclase, decrease c AMP production, and modulate ion channels, leading to reduced neurotransmitter release (e.g., substance P, glutamate) and hyperpolarization of neurons. This results in analgesia, sedation, and euphoria.
Management of moderate to moderately severe pain (FDA approved),Off-label: acute pain, postoperative pain
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate,Off-label: acute pain (e.g., postoperative), chronic pain, breakthrough cancer pain
Oral: 5-10 mg oxycodone (with 325-650 mg acetaminophen) every 4-6 hours as needed; maximum oxycodone 60 mg/day (for immediate-release) or acetaminophen 4000 mg/day. Titrate to pain control.
Initial: 2-4 mg orally every 3-4 hours; 1-2 mg intravenously/subcutaneously/intramuscularly every 2-4 hours. For opioid-naive patients, lower starting doses (e.g., 1-2 mg oral, 0.2-0.5 mg parenteral) are recommended.
Oxycodone: 3-5 hours (immediate-release), 4.5-8 hours (extended-release). Acetaminophen: 1.5-3 hours. Clinical context: Half-life may be prolonged in hepatic impairment, elderly, and renal failure.
Terminal elimination half-life: 2.0–3.0 hours in healthy adults; prolonged in renal impairment (up to 40 hours) and hepatic impairment; clinical context: supports dosing interval of 4–6 hours in normal renal function.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: acetaminophen no change, oxycodone consider 75% of usual dose; Cr Cl 10-29 m L/min: acetaminophen extend interval to q6h, oxycodone consider 50% of usual dose; Cr Cl <10 m L/min: acetaminophen avoid or 650 mg q8h, oxycodone 50% of usual dose; hemodialysis: acetaminophen 650 mg q8h, oxycodone 25-50% of usual dose.
For GFR 30-59 m L/min: administer 75% of usual dose every 4-6 hours; for GFR 10-29 m L/min: administer 50% of usual dose every 6-8 hours; for GFR <10 m L/min: administer 25% of usual dose every 8-12 hours.
Risk of addiction, abuse, and misuse; life-threatening respiratory depression; neonatal opioid withdrawal syndrome; accidental ingestion may be fatal; risk of hepatotoxicity with acetaminophen overdose.
First trimester: Risk of neural tube defects not significantly increased with therapeutic use; opioid dependence may increase risk of congenital malformations (e.g., gastroschisis). Second/third trimester: Chronic use may cause fetal opioid dependence, leading to neonatal abstinence syndrome (NAS). Late third trimester: Risk of respiratory depression in neonate if used near delivery.
Hydromorphone crosses the placenta. First trimester: no clear evidence of major malformations in human studies, but opioid use in pregnancy is associated with a small increased risk of neural tube defects and congenital heart defects. Second and third trimesters: chronic use may lead to fetal dependence and neonatal opioid withdrawal syndrome (NOWS). Use near term may cause neonatal respiratory depression.
Maximum daily acetaminophen dose is 4000 mg from all sources; prescribed combination tablets contribute to this limit. Oxycodone immediate-release duration is 3-6 hours; avoid crushing extended-release formulations. Both components have abuse potential; screen for opioid use disorder. In renal impairment, adjust dosing interval for oxycodone; avoid in Cr Cl <30 m L/min. In hepatic impairment, the acetaminophen component may be hepatotoxic; avoid in severe disease. Coadministration with serotonergic agents may precipitate serotonin syndrome. Naloxone is the reversal agent for oxycodone; acetylcysteine for acetaminophen overdose.
Hydromorphone is 5-7 times more potent than morphine; use equianalgesic dosing when converting. Avoid in patients with MAO inhibitor use within 14 days. Immediate-release onset is 15-30 min; peak effect at 30-60 min. For PCA, typical demand dose is 0.1-0.2 mg with 6-8 min lockout. Naloxone reversal may require repeated dosing due to hydromorphone's longer half-life. Consider renal impairment: dose adjustment needed for Cr Cl < 30 m L/min.
No interactions on record
No interactions on record
OXYCODONE AND ACETAMINOPHEN and HYDROMORPHONE HYDROCHLORIDE are distinct pharmacological agents. OXYCODONE AND ACETAMINOPHEN belongs to the Opioid Agonist class and is primarily used for Management of moderate to moderately severe pain (FDA approved)Off-label: acute pain, postoperative pain. HYDROMORPHONE HYDROCHLORIDE belongs to the Opioid Agonist class and is primarily used for Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequateOff-label: acute pain (e.g., postoperative), chronic pain, breakthrough cancer pain. Their specific mechanisms of action, pharmacokinetic characteristics, and side effects differ.
The maternal-fetal safety profiles of these drugs differ. OXYCODONE AND ACETAMINOPHEN carries a safety status of Category D/X, whereas HYDROMORPHONE HYDROCHLORIDE safety is classified as Category D/X. Consult a board-certified physician or healthcare specialist to establish an accurate, individualized pregnancy risk assessment before starting either therapy.
Oxycodone is extensively metabolized in the liver via CYP3A4 (primarily) and CYP2D6 (minor) to noroxycodone, oxymorphone, and other metabolites. Acetaminophen is metabolized in the liver mainly via glucuronidation and sulfation with a minor CYP2E1 pathway producing toxic NAPQI.
Hydromorphone is extensively metabolized in the liver via glucuronidation (primarily UGT2B7) to hydromorphone-3-glucuronide, which is inactive. Minor metabolism via N-demethylation to normorphine (active) and reduction to dihydroisomorphine (active).
Oxycodone: renal (primarily as noroxycodone, oxymorphone, and conjugated metabolites; <10% unchanged). Acetaminophen: renal (85-90% as sulfate and glucuronide conjugates; 2-4% unchanged; 8-10% as cysteine and mercapturate conjugates). Biliary/fecal excretion: minor (<5% for both).
Primarily renal (approximately 90% as hydromorphone-3-glucuronide and other conjugates; <7% as unchanged hydromorphone), with a small amount biliary/fecal.
Oxycodone: 38-45% (primarily to albumin). Acetaminophen: 10-25% (minimal binding).
Approximately 20–30% bound to plasma proteins (primarily albumin).
Oxycodone: 2.6-3.0 L/kg (wide distribution into tissues). Acetaminophen: 0.9-1.0 L/kg (uniformly distributed in body fluids).
1–3 L/kg; indicates extensive tissue distribution and penetration into extravascular tissues, including CNS.
Oral immediate-release: oxycodone 60-87%, acetaminophen 68-88%. Oral extended-release: oxycodone 60-87% (less variable). Rectal: variable (unspecified for this combination).
Oral immediate release: 30–40% (extensive first-pass metabolism); Oral extended release: 30–50% (first-pass effect; formulation-dependent); Rectal: approximately 30–40%; IM: nearly 100%; IV: 100%.
Child-Pugh A: no adjustment; Child-Pugh B: oxycodone reduce dose by 50%, acetaminophen maximum 2000 mg/day; Child-Pugh C: oxycodone reduce dose by 75%, acetaminophen maximum 2000 mg/day; severe hepatic impairment: avoid acetaminophen component.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50% and increase dosing interval; Class C: avoid use or reduce dose by 75% with extended intervals.
Children ≥6 months: 0.05-0.15 mg/kg oxycodone (based on oxycodone component) every 4-6 hours, maximum single dose 5 mg; acetaminophen 10-15 mg/kg/dose, maximum 75 mg/kg/day (up to 4000 mg/day). Weight-based oxycodone not to exceed adult dose.
Oral: 0.03-0.08 mg/kg/dose every 3-4 hours; Intravenous/Intramuscular: 0.015-0.02 mg/kg/dose every 4-6 hours. Maximum single dose not to exceed 5 mg.
Start at 50% of adult dose (oxycodone 2.5-5 mg every 6 hours), titrate cautiously; maximum acetaminophen 3000 mg/day due to decreased hepatic reserves; monitor for renal impairment and avoid if Cr Cl <30 m L/min.
Start at 25-50% of adult dose; increase cautiously. For oral, start with 1-2 mg every 4-6 hours. For parenteral, use 0.2-0.5 mg every 4-6 hours. Monitor for respiratory depression and constipation.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS. Hydromorphone exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Serious, life-threatening, or fatal respiratory depression may occur. Accidental ingestion, especially by children, can result in fatal overdose. Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death.
Addiction, abuse, and misuse; respiratory depression; neonatal opioid withdrawal syndrome; interactions with CNS depressants; hepatotoxicity (acetaminophen); severe hypotension; adrenal insufficiency; seizures; increased risk of overdose in patients with head injury or COPD.
Hypersensitivity to oxycodone, acetaminophen, or any component; significant respiratory depression; acute or severe bronchial asthma; paralytic ileus; known or suspected gastrointestinal obstruction; severe hepatic impairment (acetaminophen).
Avoid alcohol consumption; increases risk of hepatotoxicity from acetaminophen and potentiates CNS depression. Grapefruit juice may increase oxycodone absorption; avoid concurrent use. High-fat meals can delay oxycodone peak concentration, potentially reducing rapid pain relief. No specific restrictions with other foods.
Avoid alcohol; increased risk of severe respiratory depression, sedation, and hypotension. Grapefruit juice may increase hydromorphone plasma concentration and risk of adverse effects. High-fat meals may delay absorption of immediate-release formulations slightly but not clinically significant.
Excreted into breast milk in low concentrations. M/P ratio for oxycodone: 3.2:1; acetaminophen: approximately 1.0. Considered compatible with breastfeeding with caution; monitor infant for sedation and feeding difficulties. Avoid if maternal codeine use due to CYP2D6 ultrarapid metabolism concerns (though oxycodone less affected).
Hydromorphone is excreted into breast milk in low concentrations. The M/P ratio is not well established but estimated to be approximately 0.7-1.0. Relative infant dose is less than 2-3% of maternal weight-adjusted dose, considered compatible with breastfeeding. Monitor infant for drowsiness, respiratory depression, and feeding difficulties. Use caution with prolonged therapy.
No standard dose adjustment required for maternal pharmacokinetic changes. Increased renal clearance in pregnancy may slightly reduce acetaminophen levels, but therapeutic effect maintained. Oxycodone metabolism via CYP3A4 and 2D6; pregnancy-induced enzyme changes may alter clearance, but clinical significance unclear. Use lowest effective dose, avoid NSAIDs if co-prescribed.
Pregnancy may increase clearance of hydromorphone due to expanded plasma volume and increased renal blood flow. Effective dose may need to be increased by 20-50% in some patients, but titrate to effect and avoid supratherapeutic doses. Postpartum clearance returns rapidly, requiring dose reduction to pre-pregnancy levels.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Do not take other products containing acetaminophen (e.g., Tylenol, cold medications) to avoid exceeding the maximum daily dose of 4000 mg.,Avoid alcohol while taking this medication; liver damage risk increases with alcohol use.,Do not crush, break, or chew tablets; swallow whole to avoid rapid release of oxycodone.,This medication can cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Store securely out of sight and reach of children; dispose of unused medication via a drug take-back program.,Take with food if nausea occurs; avoid high-fat meals as they may delay absorption.,Do not stop abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering schedule.
Do not crush, chew, or break extended-release tablets; swallow whole.,Do not consume alcohol while taking hydromorphone; may cause fatal overdose.,Avoid driving or operating machinery until you know how this medication affects you.,Do not stop abruptly; withdrawal symptoms may occur. Taper under medical supervision.,Store securely, out of reach of others; dispose of unused medication via take-back programs.,Report severe drowsiness, slow breathing, or difficulty breathing immediately.,Avoid other CNS depressants (e.g., benzodiazepines, alcohol) without doctor approval.,If you have a history of adrenal insufficiency, report fatigue, weakness, or low blood pressure.